Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2)

Yann Cheli; Meri K. Tulic; Najla El Hachem; Nicolas Nottet; Arnaud Jacquel; Maeva Gesson; Thomas Strub; Karine Bille; Alexandra Picard-Gauci; Henri Montaudié; Guillaume E. Beranger; Thierry Passeron; Pierre Close; Corine Bertolotto; Robert Ballotti

doi:10.1186/s12943-021-01319-5

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2)

Yann Cheli
, Meri K. Tulic
, Najla El Hachem
, Nicolas Nottet
, Arnaud Jacquel
, Maeva Gesson
, Thomas Strub
, Karine Bille
, Alexandra Picard-Gauci
, Henri Montaudié
, Guillaume E. Beranger
, Thierry Passeron
, Pierre Close
, Corine Bertolotto
, Robert Ballotti

Research output: Contribution to journal › Comment/debate

Abstract

Following the publication of the original paper [1], the authors found out that the supplementary material is incomplete. Thus, the publication of correction to notify the readers on the error. Updated supplementary file is provided in this article.

Original language	English
Article number	21
Journal	Molecular Cancer
Volume	20
Issue number	1
DOIs	https://doi.org/10.1186/s12943-021-01319-5
State	Published - Dec 2021
Externally published	Yes

Access to Document

10.1186/s12943-021-01319-5

Fingerprint

Dive into the research topics of 'Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2)'. Together they form a unique fingerprint.

Cite this

Cheli, Y., Tulic, M. K., El Hachem, N., Nottet, N., Jacquel, A., Gesson, M., Strub, T., Bille, K., Picard-Gauci, A., Montaudié, H., Beranger, G. E., Passeron, T., Close, P., Bertolotto, C., & Ballotti, R. (2021). Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2). Molecular Cancer, 20(1), Article 21. https://doi.org/10.1186/s12943-021-01319-5

@article{3329916efcbf4445b8c378b31b413e57,

title = "Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2)",

abstract = "Following the publication of the original paper [1], the authors found out that the supplementary material is incomplete. Thus, the publication of correction to notify the readers on the error. Updated supplementary file is provided in this article.",

author = "Yann Cheli and Tulic, \{Meri K.\} and \{El Hachem\}, Najla and Nicolas Nottet and Arnaud Jacquel and Maeva Gesson and Thomas Strub and Karine Bille and Alexandra Picard-Gauci and Henri Montaudi{\'e} and Beranger, \{Guillaume E.\} and Thierry Passeron and Pierre Close and Corine Bertolotto and Robert Ballotti",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s12943-021-01319-5",

language = "English",

volume = "20",

journal = "Molecular Cancer",

issn = "1476-4598",

publisher = "BioMed Central Ltd.",

number = "1",

}

Cheli, Y, Tulic, MK, El Hachem, N, Nottet, N, Jacquel, A, Gesson, M, Strub, T, Bille, K, Picard-Gauci, A, Montaudié, H, Beranger, GE, Passeron, T, Close, P, Bertolotto, C & Ballotti, R 2021, 'Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2)', Molecular Cancer, vol. 20, no. 1, 21. https://doi.org/10.1186/s12943-021-01319-5

Correction to: ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2). / Cheli, Yann; Tulic, Meri K.; El Hachem, Najla et al.
In: Molecular Cancer, Vol. 20, No. 1, 21, 12.2021.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - ITGBL1 is a new immunomodulator that favors development of melanoma tumors by inhibiting natural killer cells cytotoxicity (Molecular Cancer, (2021), 20, 1, (12), 10.1186/s12943-020-01306-2)

AU - Cheli, Yann

AU - Tulic, Meri K.

AU - El Hachem, Najla

AU - Nottet, Nicolas

AU - Jacquel, Arnaud

AU - Gesson, Maeva

AU - Strub, Thomas

AU - Bille, Karine

AU - Picard-Gauci, Alexandra

AU - Montaudié, Henri

AU - Beranger, Guillaume E.

AU - Passeron, Thierry

AU - Close, Pierre

AU - Bertolotto, Corine

AU - Ballotti, Robert

PY - 2021/12

Y1 - 2021/12

N2 - Following the publication of the original paper [1], the authors found out that the supplementary material is incomplete. Thus, the publication of correction to notify the readers on the error. Updated supplementary file is provided in this article.

AB - Following the publication of the original paper [1], the authors found out that the supplementary material is incomplete. Thus, the publication of correction to notify the readers on the error. Updated supplementary file is provided in this article.

UR - https://www.scopus.com/pages/publications/85099991674

U2 - 10.1186/s12943-021-01319-5

DO - 10.1186/s12943-021-01319-5

M3 - Comment/debate

C2 - 33504341

AN - SCOPUS:85099991674

SN - 1476-4598

VL - 20

JO - Molecular Cancer

JF - Molecular Cancer

IS - 1

M1 - 21

ER -